Recommend Epigenetics to your librarian today. Download form here.
Sign up for Table of Contents Alerts.
The official journal of the Epigenetics Society.
Email this page
Print this page
Research Paper
Global DNA Hypomethylation in Liver Cancer Cases and Controls: A Phase I Preclinical Biomarker Development Study
Rafael Guerrero-Preston, Regina M. Santella, Adolfo Blanco, Manisha Desai, Maria Berdasco and Mario Fraga
volume 2 | issue 4
October/November/December 2007Pages: 223 - 226
Subscribe to this journal for $79/year
Background: Global genomic DNA hypomethylation is a feature of genomic DNA derived from solid and hematologic tumors in animal models and human carcinogenesis. Global genomic DNA hypomethylation may be the earliest epigenetic change from a normal to a pre-malignant cell. Objectives: To test if global hypomethylation is a good marker for early detection of cancer we used a novel quantification method of 2-deoxynucleosides to evaluate DNA methylation in liver cancer cases and controls. Methods: Frozen tissue from liver cancer patients and controls were obtained from the Cooperative Human Tissue Network. DNA was extracted using standard methods. Genomic DNA samples were boiled and treated with nuclease P1 and alkaline phosphatase. Global genomic DNA methylation patterns were obtained using HPLC for fraction separation and mass spectrometry for quantification. A two-sample t test was performed using Welchs approximation for samples with unequal variances. A Wilcoxon rank sum test was also performed. Results: A global genomic DNA methylation index measuring methylated cytidine relative to global cytidine in the genome was significantly lower (p-value = 0.001) for all cases, mean = 2.43 (95% CI, 2.08, 2.78), when compared to controls, mean = 3.55 (95% CI, 3.16, 3.93). Discussion: A correlation between global genomic DNA methylation patterns and type of liver tissue was observed. These results add to the accumulating body of evidence suggesting that global DNA hypomethylation may be a useful biomarker to distinguish between liver cancer cases and controls.
Authors
Rafael Guerrero-Preston
Columbia University; University of Puerto Rico School of Public Health
Regina M. Santella
Columbia University
Adolfo Blanco
Hospital Gregorio Marañón
Manisha Desai
Columbia University
Maria Berdasco
Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
Mario Fraga
6Spanish National Cancer Research Center (CNIO)





